Real-World Study Assesses Long-Term Blood Sugar Control with Xultophy in Type 2 Diabetes
Background
Type 2 Diabetes (T2D) is a chronic metabolic condition characterized by high blood sugar levels, requiring effective glycemic control to prevent severe complications. While randomized controlled trials establish drug efficacy under ideal conditions, understanding how treatments perform in diverse patient populations under routine care is crucial. This study aimed to address the knowledge gap regarding the long-term effectiveness of Xultophy® (IDegLira) in a real-world setting in Italy.
Study Design
Results
As this record describes a completed study protocol, specific quantitative results regarding Xultophy®'s long-term glycemic control in this 359-patient cohort are not detailed within the provided summary. The study's primary objective was to collect real-world data on how Xultophy® performs over approximately 18 months in routine clinical practice. Therefore, detailed metrics such as HbA1c reductions, weight changes, or hypoglycemia rates are not available in this summary. > The study successfully completed enrollment with 359 participants and concluded data collection on February 10, 2023, indicating that the full findings are pending publication. Further analysis of the collected data will be necessary to quantify the treatment's impact on Type 2 Diabetes management in this real-world Italian population.
Why It Matters
This study is significant because it provides valuable real-world data on the long-term effectiveness of Xultophy® in a diverse patient population, complementing controlled clinical trial findings. Understanding how a drug performs in routine clinical practice, outside of highly controlled environments, is crucial for assessing its true utility and patient adherence. The eventual publication of these results could significantly inform clinical guidelines and patient management strategies for Type 2 Diabetes, potentially optimizing treatment approaches. Future steps will involve the detailed analysis and dissemination of the collected data, which may lead to further observational studies or even inform future clinical trial designs.